
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI

Brainstorm Cell Therapeutics Inc?
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
Energy
|
We'll email you a reminder when the closing price reaches USD.
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.74
5.724
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.

What unique competitive advantages
does Brainstorm Cell Therapeutics Inc hold over its rivals?
What risks and challenges
does Brainstorm Cell Therapeutics Inc face in the near future?
Is it considered overvalued or undervalued
based on the latest financial data?
Provide an overview of the primary business activities
of Brainstorm Cell Therapeutics Inc.
Provide an overview of the primary business activities
of Brainstorm Cell Therapeutics Inc.
What unique competitive advantages
does Brainstorm Cell Therapeutics Inc hold over its rivals?
What risks and challenges
does Brainstorm Cell Therapeutics Inc face in the near future?
Summarize the latest earnings call
of Brainstorm Cell Therapeutics Inc.
Is it considered overvalued or undervalued
based on the latest financial data?
Show all valuation multiples
for Brainstorm Cell Therapeutics Inc.
Provide P/S
for Brainstorm Cell Therapeutics Inc.
Provide P/E
for Brainstorm Cell Therapeutics Inc.
Provide P/OCF
for Brainstorm Cell Therapeutics Inc.
Provide P/FCFE
for Brainstorm Cell Therapeutics Inc.
Provide P/B
for Brainstorm Cell Therapeutics Inc.
Provide EV/S
for Brainstorm Cell Therapeutics Inc.
Provide EV/GP
for Brainstorm Cell Therapeutics Inc.
Provide EV/EBITDA
for Brainstorm Cell Therapeutics Inc.
Provide EV/EBIT
for Brainstorm Cell Therapeutics Inc.
Provide EV/OCF
for Brainstorm Cell Therapeutics Inc.
Provide EV/FCFF
for Brainstorm Cell Therapeutics Inc.
Provide EV/IC
for Brainstorm Cell Therapeutics Inc.
Show me price targets
for Brainstorm Cell Therapeutics Inc made by professional analysts.
What are the Revenue projections
for Brainstorm Cell Therapeutics Inc?
How accurate were the past Revenue estimates
for Brainstorm Cell Therapeutics Inc?
What are the Net Income projections
for Brainstorm Cell Therapeutics Inc?
How accurate were the past Net Income estimates
for Brainstorm Cell Therapeutics Inc?
What are the EPS projections
for Brainstorm Cell Therapeutics Inc?
How accurate were the past EPS estimates
for Brainstorm Cell Therapeutics Inc?
What are the EBIT projections
for Brainstorm Cell Therapeutics Inc?
How accurate were the past EBIT estimates
for Brainstorm Cell Therapeutics Inc?
Compare the revenue forecasts
for Brainstorm Cell Therapeutics Inc with those of its competitors based on recent analyst estimates.
Compare the intrinsic valuations
of Brainstorm Cell Therapeutics Inc and its key competitors using the latest financial data.
Compare historical revenue growth rates
of Brainstorm Cell Therapeutics Inc against its competitors.
Analyze the profit margins
(gross, operating, and net) of Brainstorm Cell Therapeutics Inc compared to its peers.
Compare the P/E ratios
of Brainstorm Cell Therapeutics Inc against its peers.
Discuss the investment returns and shareholder value creation
comparing Brainstorm Cell Therapeutics Inc with its peers.
Analyze the financial leverage
of Brainstorm Cell Therapeutics Inc compared to its main competitors.
Show all profitability ratios
for Brainstorm Cell Therapeutics Inc.
Provide ROE
for Brainstorm Cell Therapeutics Inc.
Provide ROA
for Brainstorm Cell Therapeutics Inc.
Provide ROIC
for Brainstorm Cell Therapeutics Inc.
Provide ROCE
for Brainstorm Cell Therapeutics Inc.
Provide Gross Margin
for Brainstorm Cell Therapeutics Inc.
Provide Operating Margin
for Brainstorm Cell Therapeutics Inc.
Provide Net Margin
for Brainstorm Cell Therapeutics Inc.
Provide FCF Margin
for Brainstorm Cell Therapeutics Inc.
Show all solvency ratios
for Brainstorm Cell Therapeutics Inc.
Provide D/E Ratio
for Brainstorm Cell Therapeutics Inc.
Provide D/A Ratio
for Brainstorm Cell Therapeutics Inc.
Provide Interest Coverage Ratio
for Brainstorm Cell Therapeutics Inc.
Provide Altman Z-Score Ratio
for Brainstorm Cell Therapeutics Inc.
Provide Quick Ratio
for Brainstorm Cell Therapeutics Inc.
Provide Current Ratio
for Brainstorm Cell Therapeutics Inc.
Provide Cash Ratio
for Brainstorm Cell Therapeutics Inc.
What is the historical Revenue growth
over the last 5 years for Brainstorm Cell Therapeutics Inc?
What is the historical Net Income growth
over the last 5 years for Brainstorm Cell Therapeutics Inc?
What is the current Free Cash Flow
of Brainstorm Cell Therapeutics Inc?
Discuss the annual earnings per share (EPS)
trend over the past five years for Brainstorm Cell Therapeutics Inc.
EV/OCF
Enterprise Value to OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio is a valuation multiple that measures the value of a company, debt included, to the operating cash flow it generates.
Market Cap | EV/OCF | ||||
---|---|---|---|---|---|
US |
![]() |
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
|
5.9m USD | -0.7 | |
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD | -213 336.5 |
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
328.5B USD | 23.7 |
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
161.8B USD | 17 |
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
136.6B USD | 14.5 |
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.7B USD | -115.9 |
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -527.7 |
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
127.8B AUD | 30.9 |
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
60B USD | 13.7 |
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -82.8 |
|
US |
![]() |
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
42B USD | -895.3 |
|
US |
![]() |
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
|
Average EV/OCF:
20
|
|
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
Negative Multiple: -213 336.5 |
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
23.7
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
17
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
14.5
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Negative Multiple: -115.9 |
|
US |
E
|
Epizyme Inc
F:EPE
|
Negative Multiple: -527.7 |
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
30.9
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
13.7
|
|
US |
S
|
Seagen Inc
F:SGT
|
Negative Multiple: -82.8 |
|
US |
![]() |
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Negative Multiple: -895.3 |
|
EV/OCF Forward Multiples
Forward EV/OCF multiple is a version of the EV/OCF ratio that uses forecasted operating cash flow for the EV/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.